Four-Year Follow-Up Shows Flat Survival Curves with Frontline Checkpoint Inhibitors in dMMR Endometrial Cancer

Data presented at the 2026 Society of Gynecologic Oncology meeting examined four-year outcomes for patients with dMMR endometrial cancer treated with frontline checkpoint inhibitors.

The results showed a flat survival curve over the follow‑up period, suggesting that many patients may achieve long‑term disease control.

Investigators noted that the durability of response could translate into a reduced need for chemotherapy in this population, hinting at a potential curative effect for some patients.